Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.
Shruti U. Gandhy(Texas A&M Health Science Center), Ravi A. Madan(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Julius Strauss(National Cancer Institute), Amy Hankin(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Joseph D. Schonhoft, Fatima Karzai(National Institutes of Health), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), William D. Figg(National Cancer Institute), Alisa Tubbs(Epic Sciences (United States)), Anna Couvillon(National Institutes of Health), Audrey Gill(Epic Sciences (United States)), Sheri McMahon(National Cancer Institute), Monique Williams(National Institutes of Health), William L. Dahut(National Cancer Institute)
Cited by 1
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
|Journal of Clinical Oncology|2014|714
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422